ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.6988C>G (p.Leu2330Val) (rs148432863)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000212054 SCV000149147 likely benign not specified 2018-02-20 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Invitae RCV000122882 SCV000166140 benign Ataxia-telangiectasia syndrome 2020-12-06 criteria provided, single submitter clinical testing
Ambry Genetics RCV000115238 SCV000172962 likely benign Hereditary cancer-predisposing syndrome 2020-09-09 criteria provided, single submitter clinical testing Internal frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000212054 SCV000694339 benign not specified 2020-09-25 criteria provided, single submitter clinical testing Variant summary: ATM c.6988C>G (p.Leu2330Val) results in a conservative amino acid change located in the PIK-related kinase, FAT domain (IPR003151) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00021 in 250962 control chromosomes, predominantly at a frequency of 0.0026 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 2.6-fold of the estimated maximal expected allele frequency for a pathogenic variant (MPAF) in ATM causing Breast Cancer phenotype (0.001), suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. In addition, the variant was reported in 17/ 2559 African American women (i.e. with an allele frequency of 0.0033), who were older than age 70, and have never had cancer (in the FLOSSIES database); this allele frequency is 3.3-fold higher than the MPAF (0.001), strongly suggesting that the variant is benign. c.6988C>G has been reported in the literature in individuals affected with breast cancer (Teraoka_2001, Tavtigian_2009, Bernstein_2010) and in one individual with Lynch syndrome-associated cancer and/or colorectal polyps (Yurgelun_2015), however without strong evidence for causality. Furthermore, no association with the disease was found for this variant in a large breast cancer case-control study (Haiman_2013). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six other submitters have provided clinical-significance assessments for this variant in ClinVar after 2014 without evidence for independent evaluation, and classified the variant as VUS (2x) and likely benign (4x). Based on the evidence outlined above, the variant was classified as benign.
Mendelics RCV000122882 SCV000838587 uncertain significance Ataxia-telangiectasia syndrome 2018-07-02 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000587802 SCV000855439 uncertain significance not provided 2017-07-20 criteria provided, single submitter clinical testing
Color Health, Inc RCV000115238 SCV000902719 likely benign Hereditary cancer-predisposing syndrome 2015-12-08 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000587802 SCV001502097 likely benign not provided 2020-09-01 criteria provided, single submitter clinical testing
Natera, Inc. RCV000122882 SCV001452130 uncertain significance Ataxia-telangiectasia syndrome 2019-10-30 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.